Jefferies Financial Group began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $22.00 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price would indicate a potential upside of 44.45% from the stock’s current price.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.